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Abstract Both reductions in atherogenic lipoproteins and
increases in high-density lipoprotein (HDL) levels may
affect atherosclerosis regression. Here, the relative potential
of low-density lipoprotein (LDL) lowering and HDL raising
gene transfer strategies to induce regression of complex
murine atherosclerotic lesions was directly compared. Male
C57BL/6 LDL receptor (LDLr)
−/− mice were fed an athero-
genic diet (1.25% cholesterol and 10% coconut oil) to
induce advanced atherosclerotic lesions. A baseline group
was killed after 6 months and remaining mice were
randomized into a control progression (Adnull or saline),
an apolipoprotein (apo) A-I (AdA-I), an LDLr (AdLDLr),
or a combined apo A-I/LDLr (AdA-I/AdLDLr) adenoviral
gene transfer group and followed-up for another 12 weeks
with continuation of the atherogenic diet. Gene transfer
with AdLDLr decreased non-HDL cholesterol levels per-
sistently by 95% (p<0.001) compared with baseline. This
drastic reduction of non-HDL cholesterol levels induced
lesion regression by 28% (p<0.001) in the aortic root and
by 25% (p<0.05) in the brachiocephalic artery at 12 weeks
after transfer. Change in lesion size was accompanied by
enhanced plaque stability, as evidenced by increased
collagen content, reduced lesional macrophage content, a
drastic reduction of necrotic core area, and decreased
expression of inflammatory genes. Elevated HDL choles-
terol following AdA-I transfer increased collagen content in
lesions, but did not induce regression. Apo A-I gene
transfer on top of AdLDLr transfer resulted in additive
effects, particularly on inflammatory gene expression. In
conclusion, drastic lipid lowering induced by a powerful
gene transfer strategy leads to pronounced regression and
stabilization of advanced murine atherosclerosis.
Keywords Atherosclerosis.Advanced lesions.
Regression.Plaque stabilization.Adenoviral gene transfer.
Lipoproteins
Introduction
The primary target for prevention of cardiovascular
morbidity and mortality is dyslipidemia [1]. Lipid lowering
attenuates inflammatory stimuli within complex atheroscle-
rotic lesions leading to plaque stabilization [2]. In addition,
very intensive lipid lowering with rosuvastatin has been
associated with regression of atherosclerosis in the AS-
TEROID trial [3]. Whereas the change in low-density
lipoprotein (LDL) cholesterol is predictive of the change in
atheroma volume, it has been postulated that statins may
affect lesion regression via pleiotropic, lipid lowering-
independent effects [4, 5]. Therefore, it remains to be
demonstrated that aggressive lipid lowering itself is
sufficient to induce regression of atherosclerosis.
Plasma levels of high-density lipoprotein (HDL) choles-
terol and its major apolipoprotein (apo), apo A-I, are
inversely correlated with the risk of ischemic cardiovascular
diseases [6]. Apart from their lipid lowering properties,
statins have been reported to increase HDL cholesterol
levels by 5% to 15% [3, 7]. A recent meta-analysis of IVUS
trial data [7] indicated that statin therapy is associated with
regression of coronary atherosclerosis when LDL choles-
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increased by more than 7.5%. The addition of extended-
release niacin to statin therapy significantly increased HDL
cholesterol and slowed the progression of carotid athero-
sclerosis among individuals with known coronary heart
disease [8]. Furthermore, pilot intervention studies in
humans using infusions of both apo A-IMilano [9] and
wild-type human apo A-I [10] containing phospholipid
complexes show promising but not unequivocal results on
imaging end-points. These observations raise the question
whether a combination of an LDL lowering and HDL
raising approach could be the most effective intervention
for establishing regression of atherosclerosis.
There is a paucity of experimental animal models that
evaluate regression of advanced atherosclerotic lesions.
Indeed, although regression of fatty streaks and intermedi-
ate lesions has been convincingly demonstrated in different
animal models [11, 12], these lesions are not very relevant
from a clinical point of view. Furthermore, lipid lowering in
prior experimental regression studies of advanced athero-
sclerosis included drastic manipulations of the experimental
diet [4, 13–15], which may result in effects that occur
independent of cholesterol lowering.
Based on a series of studies directed at a continuous
improvement of expression cassettes for hepatocyte-
directed gene transfer [16–18], we developed an E1E3E4-
deleted adenoviral LDL receptor (LDLr) expressing vector
that induces a more than 95% persistent reduction of non-
HDL cholesterol in hyperlipidemic mice notwithstanding
continuation of the atherogenic diet. Our first objective was
to investigate the degree of regression of advanced lesions
with clearly developed necrotic cores induced by this LDLr
expressing vector. Secondly, to further elucidate the relative
contributions of reductions in atherogenic lipoproteins and
increases in HDL cholesterol on the progression/regression
rate of advanced atherosclerotic lesions, we compared
atherosclerosis in mice treated with LDLr, with apo A-I,
or with combined apo A-I/LDLr gene transfer. Our results
show that the drastic reduction of non-HDL cholesterol
levels after AdLDLr gene transfer induced stabilization
and powerful regression of advanced, preexisting lesions.
Increased HDL cholesterol following apo A-I gene
transfer augmented collagen content in lesions, but did
not induce regression. Gene expression profiling indi-
cated that apo A-I gene transfer on top of AdLDLr
transfer resulted in additive effects, particularly on
inflammatory gene expression.
Materials and methods
Generation of recombinant adenoviral vectors The
E1E3E4-deleted adenoviral vector AdLDLr contains the
1.2 kb DC172 promoter [18], consisting of an 890 bp
human α1-antitrypsin promoter and two copies of the
160 bp α1-microglobulin enhancer, upstream of the 5′
untranslated region (UTR) of the human apo A-I gene that
contains the first intron, and upstream of the 2.6 kb LDLr
sequence [19] and two copies of the 774 bp hepatic control
region-1. Following an EcoRI restriction, the 5′ UTR of the
human apo A-I gene together with the 2.6 kb LDLr cDNA
sequence was isolated from pGEM-A-Iintron-LDLr [19]
and subsequently ligated into the EcoRI site of pTG15203-
DC172.HCR2 [18]. Construction of the E1E3E4-deleted
adenoviral vector AdA-I containing the DC172 promoter
upstream of the genomic human apo A-I sequence and two
copies of HCR-1 has been described before [18]. The
E1E3E4-deleted control vector Adnull does not contain an
expression cassette. Construction of infectious plasmids and
large-scale production of recombinant E1E3E4-deleted
adenoviral vectors was performed as described previously
[20].
Animal studies- All experimental procedures were approved
by the Institutional Animal Care and Research Advisory
Committee of the University of Leuven. C57BL/6 LDLr
−/−
mice were purchased from Jackson Laboratories (Bar
Harbor, ME, USA). At the age of 3 months, male C57BL/
6L D L r
−/− mice received an atherogenic diet containing
1.25% (w/w) cholesterol and 10% (v/w) coconut oil ad
libitum. This diet was maintained throughout the entire
experiment. Six months after start of the diet, a baseline
reference group was euthanised for histological analysis.
Control progression mice were injected via the tail vein with
1×10
11 adenoviral particles of the control vector Adnull,
which does not contain an expression cassette, or alterna-
tively with saline buffer. Intervention groups were treated
with 5×10
10 adenoviral particles of AdA-I (AdA-I group),
5×10
10 adenoviral particles of AdLDLr (AdLDLr group), or
5×10
10 adenoviral particles of AdA-I combined with 5×10
10
adenoviral particles of AdLDLr (AdA-I/AdLDLr group).
Mice in the AdA-I and AdLDLr groups were co-injected
with 5×10
10 particles of Adnull to avoid differences in the
total vector dose. Blood was collected after an overnight
fast by puncture of the retro-orbital plexus and plasma was
immediately isolated by centrifugation at 1,100 g for
10 min and stored at −20 °C. Twelve weeks after gene
transfer or saline injection, mice of the control progression
group or interventions groups were killed for histological
analysis.
Plasma lipid analysis Please see “Materials and methods”
in the Electronic supplementary materials.
Human apo A-I enzyme immunoassay Please see “Materials
and methods” in the Electronic supplementary materials.
556 J Mol Med (2011) 89:555–567Histological analysis Please see “Materials and methods”
in the Electronic supplementary materials.
Gene expression profiling Please see “Materials and methods”
in the Electronic supplementary materials.
Statistical analysis All data are expressed as means ±
standard error of the mean (SEM). Areas under the curve
were calculated using Prism4 (GraphPad Software, San
Diego, CA, USA). Lipid and histological parameters were
compared by analysis of variance followed by Tukey’s
multiple comparison post-test or when indicated by
Kruskal–Wallis test followed by Dunn’s multiple compari-
son post-test using Instat3 (GraphPad Software). A two-
sided p value of less than 0.05 was considered statistically
significant.
Results
AdLDLr gene transfer significantly lowers non-HDL
cholesterol levels whereas AdA-I gene transfer increases
HDL cholesterol levels in LDLr
−/− mice
An atherogenic diet containing 1.25% (w/w)c h o l e s t e r o l
and 10% (v/w) coconut oil was initiated in male C57BL/6
LDLr
−/− mice at the age of 3 months. Six months after start
of the diet, mice were treated with the human apo A-I
expressing vector AdA-I (n=13), the low-density lipoprotein
receptor expressing vector AdLDLr (n=12), or a combina-
tion of both vectors (AdA-I/AdLDLr) (n=12). Control
progression mice were injected with the control vector
Adnull (n= 7 )o rw i t hs a l i n e( n=6). Since no difference
occurred between the Adnull and saline injected mice, data
of both control progression groups were pooled. The
atherogenic diet was maintained throughout the entire
experiment. Figure 1a–c show the time course of total,
non-HDL, and HDL plasma cholesterol levels, respectively,
in male C57BL/6 LDLr
−/− mice of the control progression,
AdA-I, AdLDLr, and AdA-I/AdLDLr intervention group.
Average plasma total cholesterol, non-HDL cholesterol, and
HDL cholesterol levels for the 12 week period after gene
transfer are shown in Table 1. Gene transfer with AdLDLr
and AdA-I/AdLDLr decreased non-HDL cholesterol levels
persistently by 95% (p<0.001) and by 91% (p<0.001),
respectively, compared with baseline (Fig. 1a, Table 1). This
major reduction of non-HDL cholesterol occurred in the
VLDL, IDL, and LDL fractions, as indicated in Table 1.
AdA-I gene transfer resulted in a 1.5-fold (p<0.001)increase
of HDL cholesterol levels without affecting non-HDL
cholesterol levels (Fig. 1b–c, Table 1). HDL cholesterol
levels in the AdA-I/AdLDLr treatment group were 1.8-fold
Fig. 1 Time course of total
plasma cholesterol levels (a),
non-HDL plasma cholesterol
levels (b), HDL plasma choles-
terol levels (c), and total plasma
triglyceride levels (d) in male
C57BL/6 LDLr
−/− mice of the
control progression (empty
squares)( n=13), and the AdA-I
(filled triangles)( n=13),
AdLDLr (filled circles)( n=12),
and AdA-I/AdLDLr (filled
circles)( n=12) intervention
groups. An atherogenic diet
(1.25% cholesterol (w/w), 10%
coconut oil (v/w)) was initiated
26 weeks before adenoviral gene
transfer or saline injection and
maintained throughout the
experiment. The 0 week time
point corresponds to the time
point of gene transfer in the
intervention groups. All data
represent means ± SEM
J Mol Med (2011) 89:555–567 557(p<0.001) higher compared with levels in AdLDLr treated
mice, but not significantly different compared with control
progression mice. HDL cholesterol levels in AdLDLr mice
were reduced by 37% (p<0.01) compared with control
progression mice (Fig. 1c, Table 1). Human apo A-I levels
were 160±19 mg/dl and 130±12 mg/dl following AdA-I
and AdA-I/AdLDLr gene transfer, respectively.
Time course of total plasma triglyceride levels for the
four intervention groups is shown in Fig. 1d. Compared
with control progression mice, average plasma triglycerides
increased 1.4-fold (p<0.05) after AdA-I gene transfer and
were reduced by 82% (p<0.001) and 77% (p<0.001) after
AdLDLr and AdA-I/AdLDLr gene transfer, respectively.
AdLDLr and AdA-I/AdLDLr gene transfer induce pro-
nounced regression of advanced atherosclerotic lesions in the
aortic root and brachiocephalic artery of LDLr
−/− mice
Figure 2a and b show the intimal area at the aortic root
and BCA, respectively, in male C57BL/6 LDLr
−/− mice of
the baseline group (n=13), killed 6 months after feeding the
atherogenic diet, and in male C57BL/6 LDLr
−/− mice
12 weeks after transfer with AdA-I (n=13), AdLDLr
(n=12), or AdA-I/AdLDLr (n=12), or in the control
progression group (n=13). Representative histological
sections of atherosclerotic lesions are shown in Fig. 3.
Feeding an atherogenic diet to male C57BL/6 LDLr
−/− mice
for a period of 6 months resulted in the development of
Table 1 Averagetotal,non-HDL,VLDL,IDL,LDL,andHDLcholesterollevels(mg/dl)andaveragetotaltriglyceridelevels(mg/dl)inplasmaofmale
C57BL/6 LDLr
−/− mice for the 12-week time period in the control progression group, and in AdA-I, AdLDLr, and AdA-I/AdLDLr groups
Control progression AdA-I AdLDLr AdA-I/AdLDLr
Total cholesterol 710±18 750±13 80±7.8
§§§,### 140±6.1
§§§,###,¶¶
Non-HDL cholesterol 640±20 650±16 30±3.5
§§§,### 55±6.5
§§§,###
VLDL cholesterol 150±14 160±13 6.8±0.71
§§§,### 7.2±0.85
§§§,###
IDL cholesterol 300±12 300±8.2 9.2±0.81
§§§,### 16±1.6
§§§,###
LDL cholesterol 180±14 180±8.9 14±3.2
§§§,### 32±6.0
§§§,###
HDL cholesterol 72±3.5 108±6.6
§§§ 45±4.4
§§,### 82±4.4
##,¶¶¶
Total triglycerides 290±47 420±41
§ 53±5.0
§§§,### 67±8.5
§§§,###
Data are expressed as means ± SEM (n=13 for control progression, n=13 for AdA-I, n=12 for AdLDLr, and n=12 for AdA-I/AdLDLr).
Lipoproteins were isolated by ultracentrifugation at the time points shown in Fig. 1 and average values for the time period between 1 and
12 weeks after gene transfer were obtained by dividing the area under the curve by the time of follow-up
§p<0.05;
§§p<0.01;
§§§p<0.001, versus control progression;
##p<0.01;
###p<0.001, versus AdA-I;
¶¶p<0.01;
¶¶¶p<0.001, versus AdLDLr
Fig. 2 Average intimal area (μm
2) determined at the aortic root (a)o r
brachiocephalic artery (b) of male C57BL/6 LDLr
−/− mice of the
baseline group (n=13), killed 26 weeks after feeding the atherogenic
diet, of the control progression group (n=13), or of the AdA-I (n=13),
the AdLDLr (n=12), and AdA-I/AdLDLr (n=12) intervention groups
12 weeks after gene transfer with continuation of the atherogenic diet.
Quantifications were performed on hematoxylin and eosin stained
sections at 70 μm-spaced intervals along the entire aortic root or BCA.
Data are expressed as means ± SEM
558 J Mol Med (2011) 89:555–567Fig. 3 Representative hematoxy-
linand eosin stained sectionsof the
aortic root (left: a, c, e, g,a n di)
and brachiocephalic artery (right:
b, d, f, h,a n dj)o fm a l eC 5 7 B L / 6
LDLr
−/− mice of the baseline
group (a–b), or of male C57BL/6
LDLr
−/− mice of the control
progression (c–d),o ro ft h ed A - I ,
(e–f),A d L D L r(g–h), and AdA-I/
AdLDLr (i–j) intervention groups.
Scale bar represents 500 μm( left)
and 200 μm( right)
J Mol Med (2011) 89:555–567 559advanced atherosclerotic lesions in both the aortic root and
BCA, as shown for the baseline group in Fig. 3a, b. At the
aortic root, intimal area in the control progression group
was 1.5-fold (p<0.001) higher compared with baseline
mice (Fig. 2a). AdLDLr and AdA-I/AdLDLr gene transfer
reduced aortic root intimal area by 28% (p<0.001) and 32%
(p<0.001), respectively, compared with the baseline group
(Fig. 2a). No significant difference in aortic root intimal
area was observed between AdLDLr and AdA-I/
AdLDLr treated mice. After AdA-I transfer, intimal
area at the aortic root increased 1.3-fold (p<0.01)
compared with baseline mice and was not significantly
lower than in control progression mice. At the level of
the BCA, intimal area increased 1.6-fold (p<0.001)
during the 12 weeks after Adnull transfer or saline
injection compared with baseline mice (Fig. 2b). After
AdLDLr and AdA-I/AdLDLr gene transfer, intimal area
at the BCA decreased by 25% (p< 0 . 0 5 )a n db y1 7 %
(p=NS), respectively, compared with baseline mice
(Fig. 2b). Intimal area at the BCA in the AdA-I transfer
group was not significantly different compared with the
baseline group.
Regression of atherosclerosis following AdLDLr and
AdA-I/AdLDLr gene transfer is not associated with
negative remodeling Please see “Results” in the Electronic
supplementary materials.
AdLDLr and AdA-I/AdLDLr gene transfer promote
stability of complex atherosclerotic plaques in LDLr
−/− mice.
To evaluate whether gene transfer also affects the
composition and thereby the stability of advanced athero-
sclerotic plaques in the aortic root and BCA, the amount of
smooth muscle cells (SMC), collagen, macrophages, T
cells, and lipids the size of the necrotic core was quantified.
Both relative and absolute data are presented in Table 2.
Representative sections of the aortic root and BCA stained
for different histological parameters are shown for all
groups of mice in Figs. 4 and 5, respectively. At both
locations, atherosclerotic lesions in baseline mice were
complex and characterized by lipid-rich necrotic cores filled
with cellular debris and covered by a fibrous cap consisting
of smooth muscle cells, collagen, and a foam cell infiltrate
(Figs. 4 and 5). At the aortic root, relative intimal SMC
content was not significantly changed in the control
progression and AdA-I groups compared with baseline
mice, whereas AdLDLr and AdA-I/AdLDLr transfer
increased the percentage SMC covered intimal area by
2.0-fold (p<0.01) (Table 2). At the level of the BCA,
relative SMC-positive intimal area was not significantly
different in the control progression and intervention groups
compared with baseline (Table 2). Relative collagen area in
the intima at the aortic root was similar in the control
progression group compared with baseline mice, but was
1.8-fold (p<0.01), 1.5-fold (p=NS), and 2.0-fold (p<0.001)
increased during the 12 weeks after AdA-I, AdLDLr, and
AdA-I/AdLDLr transfer, respectively (Table 2). Similar
results were obtained at the level of the BCA, where AdA-I,
AdLDLr, and AdA-I/AdLDLr transfer increased the per-
centage of collagen covered intimal area by 1.5-fold
(p=NS), 1.7-fold (p<0.05), and 1.8-fold (p<0.05), respec-
tively, compared with baseline mice (Table 2). Relative
macrophage covered intimal area at the aortic root
decreased 2.2-fold (p<0.001), 2.9-fold (p<0.001), 4.8-fold
(p<0.001), and 4.1-fold (p<0.001) during the 12 weeks
following Adnull or saline injection, or transfer with AdA-I,
AdLDLr, and AdA-I/AdLDLr, respectively, compared with
baseline mice (Table 2). At the level of the BCA, relative
macrophage-positive intimal area was not significantly
affected in the control progression and AdA-I groups, but
was 1.5-fold (p=NS) and 1.4-fold (p=NS) decreased after
AdLDLr and AdA-I/AdLDLr transfer, respectively, com-
pared with the baseline group. Intimal T cell density,
expressed as the number of CD3-positive cells per surface
unit of intimal area, increased 2.1-fold (p<0.01) and 1.7-fold
(p=NS) at the level of the aortic root in the control
progression and AdA-I treated group, respectively, compared
with baseline mice, but did not markedly change in the
AdLDLr and AdA-I/AdLDLr groups. At the level of the
BCA, intimal T cell density increased during the 12 weeks
after intervention, without any significant difference between
all five groups (Table 2). Since lymphocyte infiltration
predominantly occurs in the lamina adventitia, we also
quantified T cell number in the adventitia. A decrease of
adventitial T cell density was observed after AdLDLr and
AdA-I/AdLDLr gene transfer. Please see “Results” in the
Electronic supplementary materials for detailed analysis of
these data. Relative lipid-positive intimal area at the aortic
root did not differ between the five groups, but when
expressed in absolute values, intimal lipid area was
significantly increased in the control progression and AdA-
I groups, whereas AdLDLr and AdA-I/AdLDLr gene
transfer resulted in a slight decrease of the absolute intimal
lipid content, compared with baseline mice (Table 2). At the
BCA, relative lipid-positive intimal area decreased 1.5-fold
(p=NS) and 1.4-fold (p=NS) after AdLDLr and AdA-I/
AdLDLr gene transfer, which corresponds with a 1.8-fold
(p<0.01) and 1.7-fold (p<0.05) lower relative area com-
pared with control progression mice, respectively.
Quantification of necrotic core size, which is a determinant
of plaque vulnerability, revealed that lesional necrotic core
area was drastically reduced following AdLDLr and AdA-I/
AdLDLr gene transfer. Please see “Results” Electronic
supplementary materials for extensive discussion of these
data.
Quantification of intimal apoptosis by immunohisto-
chemical staining for active caspase 3. Please see “Results”
Electronic supplementary materials.
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562 J Mol Med (2011) 89:555–567Gene expression profiling reveals changed expression of
genes involved inlipid metabolism and reduced expression of
inflammatorygenes after AdLDLrorAdA-I/AdLDLrtransfer
To further explore the effects of lipoprotein modifying
interventions on the molecular composition of atherosclerotic
plaques, the expression of atherosclerosis-related genes in the
aortic root and BCA of baseline mice, control progression
mice, and mice treated with AdA-I, AdLDLr, and AdA-I/
AdLDLr were analyzed using Mouse Atherosclerosis RT
2
Profiler PCR Arrays (Electronic supplementary materials
(Table 1)). This analysis shows that the expression of several
genes involved in lipid transport and metabolism was
significantly affected by AdLDLr or AdA-I/AdLDLr gene
transfer. Both in the aortic root and BCA, ATP-binding
cassette transporter A1 (Abca1), macrophage scavenger
receptor 1 (Msr1), and apolipoprotein E (Apoe) were down-
regulated following AdLDLr and AdA-I/AdLDLr transfer
compared with baseline mice. Several inflammatory genes
were down-regulated in AdLDLr and AdA-I/AdLDLr treated
mice including the chemokines MCP-1 (Ccl2) and Gro-1
(Cxcl1), the chemokine receptors CD191 (Ccr1) and CD192
(Ccr2), and the cytokines interleukin-1α (Il1a), interleukin-
1β (Il1b), and interferon-γ (Ifng). Down-regulation of
inflammatory genes was mostly more pronounced in the
combined AdA-I/AdLDLr gene transfer group compared
with the AdLDLr group, as was the case for Ccl2, Cxcl1,
Ccr1,andIl-1a (Electronic supplementarymaterials (Table1)).
In addition to inflammatory genes, the adhesion molecules
intercellular adhesion molecule (Icam1), vascular cell adhe-
sion molecule 1 (Vcam1), integrin αX (Itgax), integrin β2
(Itgb2), and p-selectin (Selp) were down-regulated after
AdLDLr and AdA-I/AdLDLr transfer. Secreted phosphopro-
tein 1 (Spp1; also called osteopontin), which has an important
role in plaque calcification, was also significantly down-
regulated at the aortic root and BCA after AdLDLr and AdA-
I/AdLDLr gene transfer (Electronic supplementary materials
(Table 1)). AdA-I gene transfer alone did not have any major
impact on gene expression in lesions.
LDLloweringgenetransfermaybeaccompaniedbyashift
of macrophages toward a more favorable M2 phenotype.
Please see “Results” in the Electronic supplementary
materials.
Regression of atherosclerosis following AdLDLr and
AdA-I/AdLDLr gene transfer is not accompanied by an up-
regulation of the chemokine receptor CCR7 in atheroscle-
rotic lesions. Please see “Results” in the Electronic
supplementary materials.
Discussion
The main findings of the present study are that (1) a drastic
reduction of non-HDL cholesterol levels following gene
transfer with LDLr expressing E1E3E4-deleted adenoviral
vectors in C57BL/6 LDLr
−/− mice causes pronounced
regression of advanced atherosclerotic lesions in the
aortic root and brachiocephalic artery; (2) AdLDLr gene
transfer promotes the stability of advanced atherosclerotic
lesions as evidenced by an increase in collagen content, a
decrease in lesion macrophage content, a decrease in
necrotic core area, and a reduced expression of inflam-
matory genes; (3) increased HDL cholesterol following
apo A-I gene transfer elevates collagen content in
lesions, but does not induce regression; and (4) HDL
raising gene transfer on top of AdLDLr transfer results in
additive effects at the level of gene expression, particu-
larly on inflammatory gene expression.
Promoting regression and stabilization of advanced
atherosclerotic lesions is a major goal for decreasing
morbidity and mortality from ischemic cardiovascular
diseases [2]. In the current study, we studied lesions at
two different topographic sites, namely in the aortic root, an
elastic artery where lesions develop earliest in mice, and in
the brachiocephalic artery [13], a muscular artery prone to
rapid development of complex lesions. Feeding an athero-
genic diet to male C57BL/6 LDLr
−/− mice for a period of
6 months resulted at these two sites in the development of
advanced lesions in the baseline group containing lipid-rich
necrotic cores, cholesterol clefts, fibrous caps, and a foam
cell infiltrate. In this study, we investigated the relative
potential of LDL lowering and HDL raising interventions to
induce regression and plaque stabilization. Gene transfer
with AdLDLr, an E1E3E4-deleted adenoviral vector con-
taining a potent hepatocyte-specific expression cassette
[18], constitutes, to the best of our knowledge, the most
potent lipid lowering intervention. Non-HDL cholesterol
levels were reduced by more than 95%. A unique feature of
the current study was that regression of advanced athero-
sclerotic lesions was investigated in an experimental
protocol with maintenance of the atherogenic diet through-
out the experiment. This is in sharp contrast with other
regression studies in mice, rabbits, swine, and non-human
primates in which lipid lowering was achieved via
withdrawal of the dietary stimulus or in which lipoprotein
modifying interventions were accompanied by dietary
manipulations [4, 13–15]. Importantly, modification of the
diet may affect atherosclerotic lesions independent of
cholesterol lowering, rendering the interpretation of such
studies complex. For example, withdrawal of saturated fat
may have beneficial effects on atherosclerosis independent
of lipoprotein cholesterol levels by decreasing selective
cholesterol uptake in the arterial wall [21] and by reducing
vascular inflammation [22]. Since AdLDLr gene transfer is
a highly selective lipid lowering intervention, lipid
lowering-independent effects did not contribute to regres-
sion in the current study. Atheroma volume was decreased
J Mol Med (2011) 89:555–567 563564 J Mol Med (2011) 89:555–567by 28% and 25% in the aortic root and in the brachioce-
phalic artery, respectively, following AdLDLr gene transfer.
To put these numbers into perspective, a comparison with
atherosclerosis regression in humans is interesting. The
median reduction of plaque volume in the ASTEROID trial
was 6.8% following a 53% reduction of LDL cholesterol
levels to 61 mg/dl induced by high-dose rosuvastatin
therapy [3].
Besides the pronounced reduction of atheroma volume,
AdLDLr and AdA-I/AdLDLr gene transfer were accompa-
nied by important histological and molecular changes
known to be associated with increased plaque stability
[23]. Similarly as has been reported in rabbit lesions after
dietary lipid lowering [23], intimal collagen content was
significantly increased in both lipid lowering groups.
Correspondingly, expression of interferon-γ,aTc e l l
lymphokine known to reduce collagen biosynthesis by
smooth muscle cells [24], was decreased. AdLDLr and
AdA-I/AdLDLr gene transfer decreased lesional macro-
phage content, which was associated with a decreased
intimal expression of Abca1, Apoe, and Msr1, all known to
be expressed by macrophages [25–27]. Furthermore, apo B
lowering gene transfer decreased intimal expression of
cytokines, chemokines, chemokine receptors, and adhesion
molecules. This indicates that inflammation in advanced
atherosclerotic lesions can be reduced by lipid lowering
itself. Other plaque stabilizing effects of apo B lowering
gene transfer include a reduction of intimal expression of
matrix metalloproteinase-3 (MMP-3 or stromelysin-1)
and secreted phosphoprotein 1 (Spp1 or osteopontin),
which is involved in weakening the connective tissue
matrix [28] and in regulating plaque calcification [29],
respectively.
Elevated HDL cholesterol following AdA-I gene transfer
increased intimal collagen content compared with baseline
mice but did not induce regression of atherosclerosis.
Lesional macrophage content was reduced following
AdA-I gene transfer in the aortic root but not in the
brachiocephalic artery. Continued progression of advanced
atherosclerotic lesions notwithstanding increased HDL
cholesterol has also been observed in a another murine
model by Rong et al. [30]. In a recent study on the effect of
HDL raising gene transfer on advanced atherosclerotic
lesions in rabbits, we showed that increased HDL choles-
terol following gene transfer resulted in an inhibition of
progression of atherosclerosis and in a reduction of neutral
lipid content in the intima compared with baseline [31]. The
absence of similar effects of AdA-I gene transfer on
advanced lesions in the current study may be related to
the very high levels of pro-atherogenic lipoproteins (non-
HDL cholesterol levels of approximately 650 mg/dl), which
override the effects of increased HDL cholesterol. Further-
more, baseline HDL cholesterol levels in C57BL/6 LDLr
−/−
mice fed an atherogenic diet were significantly higher than
in C57BL/6 apo E
−/− mice [32] or in wild-type C57BL/6
mice [33] and consequently, the relative increase of HDL
cholesterol following apo A-I gene transfer was less
pronounced in the current study than observed in other
models [32, 33].
Additive effects of raising HDL cholesterol levels in the
setting of a drastic reduction of apo B containing lipo-
proteins were observed at the molecular level. The
reduction of intimal expression of several inflammatory
genes was significantly more pronounced in the AdA-I/
AdLDLr group compared with the AdLDLr group, which is
consistent with the anti-inflammatory effects of HDL. No
major differences in cellular composition of atherosclerotic
lesions were observed between the AdLDLr group and the
AdA-I/AdLDLr group, particularly in the aortic root.
Therefore, comparison of gene expression profiling results
between these two groups highlights differences at the
cellular level and not simply differences of cellularity of the
plaque. The less pronounced increase of HDL cholesterol in
the AdA-I/AdLDLr group compared with the AdA-I group
may be partially explained by catabolism of apo E
containing HDL particles via the LDL receptor in the
AdA-I/AdLDLr group but is likely predominantly due to a
reduced transfer of free cholesterol from LDL to HDL in
the setting of low LDL cholesterol levels.
The current study represents a head to head comparison
of LDL lowering and HDL raising gene transfer strategies
using vectors with exactly the same transcriptional regula-
tory sequences. Nevertheless, the relative effect of human
apo A-I transfer on HDL cholesterol levels was moderate
compared with the drastic lowering of pro-atherogenic
lipoproteins after AdLDLr gene transfer. A further limita-
tion of the current study is that an increase of triglycerides
occurred after AdA-I transfer. In contrast, no change of
triglycerides was previously observed after human apo A-I
transfer in C57BL/6 apo E
−/− mice fed normal chow [34].
Therefore, the increase of triglycerides after human apo A-I
transfer is model and diet dependent. Enrichment of
lipoproteins with triglycerides could have hampered lesion
regression.
In conclusion, drastic lowering of apo B containing
lipoproteins following LDLr gene transfer in hypercholes-
terolemic mice results in a pronounced regression and a
Fig. 5 Histological composition of intimal lesions located at the
brachiocephalic artery of male C57BL/6 LDLr
−/− mice of the baseline
group, the control progression group, and the AdA-I, AdLDLr, and
AdA-I/AdLDLr intervention groups. Representative photomicro-
graphs show α-actin-positive smooth muscle cells, Sirius red-stained
collagen, Sirius red-stained collagen viewed under polarized light,
Mac-3-positive macrophages, CD3-positive T cells, Verhoeff–Van
Gieson staining, and Verhoeff–Van Gieson-stained images digitally
processed into monochrome, which were used for quantification of
intimal lipid content. Scale bar represents 100 μm

J Mol Med (2011) 89:555–567 565more stable phenotype of advanced atherosclerotic lesions.
HDL raising gene transfer on top of AdLDLr transfer
results in additive effects at the level of gene expression,
particularly on inflammatory gene expression.
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